Prevent preclinical drug development program: preclinical efficacy and intermediate biomarkers; task order: prevention of colorectal cancer with ipsc-based vaccine
Ended Awarded Last action
- Contract number
- 75N91021F00001
- Awardee
-
The Univeristy Of Texas M.d. Anderson Cancer Center UEI S3GMKS8ELA16 Part of University Of Texas System
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $632,712
Award facts
- Contract value 100% obligated
- $632,712.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Houston, TX 77030, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$3,000 | |
| Other Administrative Action | $0 | |
| Original award | $635,712 |
About this award
The University of Texas M.D. Anderson Cancer Center has been awarded a $632,712 firm fixed price delivery order against the PREVENT Preclinical Drug Development Program multiple award IDIQ contract by the National Cancer Institute, part of the National Institutes of Health within the Department of Health and Human Services. The delivery order is for the task of conducting preclinical efficacy and intermediate biomarker studies to develop an induced pluripotent stem cell-based vaccine for the prevention of colorectal cancer, in support of the PREVENT program's goal of advancing promising candidates into early clinical trials. Work will be performed in Houston, Texas over an approximately 20-month period concluding in February 2023. No subcontractors or set-asides were identified.
Quick answers
Who was awarded contract 75N91021F00001?
75N91021F00001 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by National Cancer Institute (National Institutes of Health) on May 12, 2021.
How much is contract 75N91021F00001 worth?
The government has obligated $632,712 on 75N91021F00001.
Is contract 75N91021F00001 an order under another contract?
Yes. 75N91021F00001 is a delivery order under 75N91019D00021, an indefinite delivery contract, on PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91021F00001 competed?
The extent of competition for 75N91021F00001 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award